As our recent studies in the IHKA model demonstrate that enduring genetic inhibition of STAT3 activity in excitatory neurons [30] prevents epilepsy progression, future studies should also investigate whether pharmacological inhibition of STAT3 activity with RUXO after the onset of epilepsy provides a similar benefit. The gene discussed is STAT3; the disease is epilepsy.